Skip to main content

Table 1 Baseline of characteristics of the included trials

From: Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis

Source

Number of patents

Age

Male

Diabetes

Diameter stenosis (%)

Vessel diameter (mm)

Lesion length (mm)

Inclusion criteria

Exclusion criteria

Primary outcomes

Secondary outcomes

Other outcomes

Follow-up duration, year

Funding

SPIRIT II [4547]

EES*

223

62 ± 10

158

51

61 ± 12

2.70 ± 0.52

13.0 ± 5.7

1. Ischemia and vessel size 2.5–4.25 mm and lesion length ≤ 28 mm;

2. A percentage diameter

stenosis (DS) 50 %−99 %

1. Recent MI,LVEFx ≤ 30 %;

2. LM§ heavily calcified lesion;

3. Visible thrombus

.MI

ST††

ID-TLR# ID-MACEll

CABG**

3.4,5

Abbott vascular

PES

77

62 ± 9

61

20

59 ± 10

2.82 ± 0.58

13.2 ± 6.4

  

SPIRIT III [48, 49]

EES*

669

63.2 ± 10.5

469

198

70.0 ± 13.3

2.77 ± 0.45

14.7 ± 5.6

1. Stable, unstable angina; 2. Ischemia with vessel size 2.5–3.75 mm and lesion length ≤ 28 mm

1. Recent MI,LVEFx < 30 %;

2. LM§ bifurcation;

3. BG;

4. Calcification;

5. Thrombus

MAGE‡‡

Cardiac death

MI

ST††

TLRxx TVR§§

TLFllll

3.5

Abbott vascular

PES

332

62.8 ± 10.2

218

92

69.4 ± 13.6

2.76 ± 0.46

14.7 ± 5.7

  

SPIRIT IV

[50]

EES*

2460

63.3 ± 10.5

1664

787

72.3 ± 12.6

1. Stable, unstable angina; 2. Ischemia with vessel size 2.5–4.25 mm and lesion length ≤ 28 mm

1. Recent MI,LVEFx < 30 %;

2. LM§ bifurcation;

3. lcomplex lesions;

4. Totally occluded vessels;

5. Large bifurcations;

6. Excessive calcification;

7. Tortuosity;

8. Angulation;

9. Thrombus

MAGE‡‡

Cardiac death

MI

.ST††

TLRxx ID-TLR#

TLFllll

3

Abbott vascular

PES

1230

63.3 ± 10.2

833

399

72.0 ± 12.8

  
  1. Abbreviations: *:everolimus-eluting stent; :paclitaxel-eluting stent; :myocardial infarction; xLVEF: left ventricular ejection fraction; §:left main; ll:major adverse cardiac events; #:ischemia-driven target lesion revascularization; **:coronary artery bypass graft; ††:sent thrombus ; ‡‡ :major adverse cardiac events; xx:target lesion revascularization; §§:target vessel revascularization; llll:Target lesion failure